Untitled-1.png

NCL Applauds Califf Nomination, Encourages FDA to Focus on CBD

Last week, President Biden nominated Dr. Robert Califf to serve as Commissioner of the U.S. Food and Drug Administration. NCL Executive Director Sally Greenberg weighed in with the following statement:


“NCL welcomes Dr. Robert Califf to the important role as Commissioner of the FDA. We have worked with Dr. Califf during previous administrations and can attest that he brings a longstanding commitment to FDA’s crucial role of overseeing the nation’s food and drug industry as well as medical devices and cosmetics. Dr. Califf has a long list of priorities ahead of him, and it is our hope that we can look forward to working with him on matters of consumer protection.


Among NCL’s consumer safety concerns is the proliferation of unregulated CBD products in the marketplace, encouraging confidence in vaccines for the prevention of COVID-19 and other infectious diseases, ensuring accurate food and nutrition labeling information for consumers, and making prescription drugs accessible and affordable for all Americans..."


To read the full statement, click here.